Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases Earnings Results, Beats Expectations By $0.06 EPS

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued its quarterly earnings results on Tuesday. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.23 by $0.06, Zacks reports. The business had revenue of $12.53 billion for the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.61%. Bayer Aktiengesellschaft updated its FY 2026 guidance to 1.200-1.346 EPS.

Bayer Aktiengesellschaft Stock Up 3.0%

OTCMKTS:BAYRY opened at $13.98 on Wednesday. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The stock has a 50 day moving average of $12.43 and a 200-day moving average of $12.09. The firm has a market capitalization of $54.94 billion, a PE ratio of -21.84, a price-to-earnings-growth ratio of 4.35 and a beta of 0.55. Bayer Aktiengesellschaft has a 52 week low of $7.19 and a 52 week high of $15.23.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BAYRY. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 19th. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a research note on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a report on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.